A61K 39/0011
Cancer antigens
Official title: {Cancer antigens}
A61K39/0011 (Cancer antigens) appears on 4,245 US grants and 7,771 published applications in this corpus.
Search patents in A61K- Granted patents
- 4,245
- Published applications
- 7,771
- Assignees
- 2,118
- Inventors
- 9,512
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 1 | 0 |
| 1979 | 3 | 0 |
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 3 | 0 |
| 1987 | 2 | 0 |
| 1988 | 4 | 0 |
| 1989 | 10 | 0 |
| 1990 | 4 | 0 |
| 1991 | 1 | 0 |
| 1992 | 3 | 0 |
| 1993 | 9 | 0 |
| 1994 | 2 | 0 |
| 1995 | 3 | 0 |
| 1996 | 5 | 0 |
| 1997 | 13 | 0 |
| 1998 | 29 | 0 |
| 1999 | 32 | 0 |
| 2000 | 25 | 0 |
| 2001 | 43 | 16 |
| 2002 | 39 | 80 |
| 2003 | 31 | 519 |
| 2004 | 21 | 162 |
| 2005 | 23 | 128 |
| 2006 | 36 | 131 |
| 2007 | 103 | 107 |
| 2008 | 107 | 119 |
| 2009 | 64 | 161 |
| 2010 | 78 | 188 |
| 2011 | 83 | 194 |
| 2012 | 90 | 168 |
| 2013 | 118 | 197 |
| 2014 | 113 | 217 |
| 2015 | 141 | 268 |
| 2016 | 171 | 340 |
| 2017 | 191 | 381 |
| 2018 | 235 | 428 |
| 2019 | 345 | 531 |
| 2020 | 365 | 590 |
| 2021 | 330 | 600 |
| 2022 | 317 | 633 |
| 2023 | 285 | 524 |
| 2024 | 311 | 464 |
| 2025 | 271 | 375 |
| 2026 | 176 | 250 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 39/001102Receptors, cell surface antigens or cell surface determinants1,152
- A61K 39/001154Enzymes384
- A61K 39/001184Cancer testis antigens326
- A61K 39/001152Transcription factors278
- A61K 39/001169Tumor associated carbohydrates247
- A61K 39/001193Prostate associated antigens e.g. prostate stem cell antigen [psca]220
- A61K 39/001148Regulators of development218
- A61K 39/00119Melanoma antigens216
All 17 subgroupsShow fewer
- A61K 39/00118From embryonic or fetal origin191
- A61K 39/001136Cytokines125
- A61K 39/001166Adhesion molecules108
- A61K 39/00113Growth factors94
- A61K 39/001176Heat shock proteins52
- A61K 39/001196Fusion proteins originating from gene translocation in cancer cells34
- A61K 39/001174Proteoglycans33
- A61K 39/001144Hormones30
- A61K 39/001178Tumor rejection antigen precursor [trap]0
Recent patents
- Lipid nanoparticles comprising sterols and mRNA6 Oct 2026US 12,751,999 B2eTheRNA Immunitherapies NV
- Immunostimulatory adjuvants6 Oct 2026US 12,752,000 B2Orionis Biosciences BV
- NKG2A-targeting antibody and use thereof6 Oct 2026US 12,753,231 B2Bioheng Therapeutics Limited
- FOXM1-derived peptide, and vaccine including same29 Sep 2026US 12,747,265 B2Oncotherapy Science, Inc.
- Selection of cancer mutations for generation of a personalized cancer vaccine29 Sep 2026US 12,749,556 B2Nouscom AG
- Modular multiplatform system for mrna drug production8 Oct 2026US 2026/0306407 A1BioNTech SE
- Timp3-derived teipp neoantigens and uses thereof8 Oct 2026US 2026/0306599 A1
- Sarcoma cancer vaccines and uses thereof8 Oct 2026US 2026/0306600 A1
- A novel non-stoichiometric multi-element adjuvant (nsma) and composition thereof8 Oct 2026US 2026/0306624 A1Magvitae Innovations Inc
- Treatment involving non-immunogenic rna for antigen vaccination8 Oct 2026US 2026/0306625 A1BioNTech SE
Most cited
By later US patents
- Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines290US 6,218,371 B1University of Iowa Research Foundation · 2001
- Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy258US 8,034,334 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2011
- Immunotherapy against several tumors, such as lung cancer, including NSCLC198US 10,071,148 B2Immatics Biotechnologies GmbH · 2018
- Application of mRNA for use as a therapeutic agent for tumorous diseases194US 8,217,016 B2CureVac AG · 2012
- Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides190US 5,679,647 AThe Regents of the University of California · 1997